These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

417 related items for PubMed ID: 11792343

  • 1. Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
    Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q.
    Am J Cardiol; 2002 Jan 15; 89(2):204-9. PubMed ID: 11792343
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.
    Circulation; 2001 Nov 06; 104(19):2280-8. PubMed ID: 11696466
    [Abstract] [Full Text] [Related]

  • 3. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
    Langman MJ, Jensen DM, Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.
    JAMA; 1999 Nov 24; 282(20):1929-33. PubMed ID: 10580458
    [Abstract] [Full Text] [Related]

  • 4. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
    Gertz BJ, Krupa D, Bolognese JA, Sperling RS, Reicin A.
    Curr Med Res Opin; 2002 Nov 24; 18(2):82-91. PubMed ID: 12017215
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
    Watson DJ, Harper SE, Zhao PL, Bolognese JA, Simon TJ.
    MedGenMed; 2001 Nov 16; 3(4):6. PubMed ID: 11965201
    [Abstract] [Full Text] [Related]

  • 6. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct 16; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis.
    Watson DJ, Harper SE, Zhao PL, Quan H, Bolognese JA, Simon TJ.
    Arch Intern Med; 2000 Oct 23; 160(19):2998-3003. PubMed ID: 11041909
    [Abstract] [Full Text] [Related]

  • 8. Treatment of patients with osteoarthritis with rofecoxib compared with nabumetone.
    Weaver AL, Messner RP, Storms WW, Polis AB, Najarian DK, Petruschke RA, Geba GP, Tershakovec AM.
    J Clin Rheumatol; 2006 Feb 23; 12(1):17-25. PubMed ID: 16484875
    [Abstract] [Full Text] [Related]

  • 9. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C.
    Circulation; 2006 Jun 27; 113(25):2906-13. PubMed ID: 16785336
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
    Day R, Morrison B, Luza A, Castaneda O, Strusberg A, Nahir M, Helgetveit KB, Kress B, Daniels B, Bolognese J, Krupa D, Seidenberg B, Ehrich E.
    Arch Intern Med; 2000 Jun 26; 160(12):1781-7. PubMed ID: 10871971
    [Abstract] [Full Text] [Related]

  • 11. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group.
    Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, Sperling R, Daniels B.
    Arch Fam Med; 2000 Jun 26; 9(10):1124-34. PubMed ID: 11115219
    [Abstract] [Full Text] [Related]

  • 12. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
    Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ.
    Curr Med Res Opin; 2004 Oct 26; 20(10):1539-48. PubMed ID: 15462687
    [Abstract] [Full Text] [Related]

  • 13. Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal antiinflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis.
    White WB, Strand V, Roberts R, Whelton A.
    Am J Ther; 2004 Oct 26; 11(4):244-50. PubMed ID: 15266215
    [Abstract] [Full Text] [Related]

  • 14. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.
    Curr Med Res Opin; 2006 Dec 26; 22(12):2365-74. PubMed ID: 17265571
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug 26; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly.
    Morgan GJ, Poland M, DeLapp RE.
    Am J Med; 1993 Aug 09; 95(2A):19S-27S. PubMed ID: 8356998
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer.
    Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, Stokes JC, Julier P, Iveson C, Duvvuri R, McConkey CC, VICTOR Trial Group.
    N Engl J Med; 2007 Jul 26; 357(4):360-9. PubMed ID: 17652651
    [Abstract] [Full Text] [Related]

  • 19. Rofecoxib: a review of its use in the management of osteoarthritis, acute pain and rheumatoid arthritis.
    Matheson AJ, Figgitt DP.
    Drugs; 2001 Jul 26; 61(6):833-65. PubMed ID: 11398914
    [Abstract] [Full Text] [Related]

  • 20. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E, Watson DJ, Kong SX, Toubouti Y, LeLorier J.
    Pharmacoepidemiol Drug Saf; 2007 May 26; 16(5):493-503. PubMed ID: 17086567
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.